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Research in Translation
T
he incidence of tick-borne 
diseases has drastically increased 
over the past few years [1,2], 
resulting in a marked increase in 
research on tick–host–pathogen 
interactions. As a result, the knowledge 
on molecules present in tick saliva 
and their function has signiﬁcantly 
expanded [3,4]. Ticks are obligate 
hematophagous ectoparasites, and 
hundreds of tick species are distributed 
worldwide. While taking a blood 
meal, ticks are attached to their host 
for several days and introduce saliva 
into the host skin. Like saliva from 
other hematophagous animals, such 
as mosquitoes, ﬂies, leeches, and 
nematode species, tick saliva contains 
a wide range of physiologically 
active molecules that are crucial for 
attachment to the host or for the 
transmission of pathogens [5], and 
that interact with host processes, 
including coagulation and ﬁbrinolysis, 
immunity and inﬂammation, and 
angiogenesis [3,6,7]. In this article, 
we discuss molecules in tick saliva that 
have been intensively studied in vitro or 
in animal models for human diseases, 
and that, due to their speciﬁcity, are 
potential future anticoagulant or 
immunosuppressive agents. We also 
discuss how immunologically targeting 
speciﬁc tick salivary proteins could 
prevent the transmission of tick-borne 
pathogens from the tick to the host.
Anticoagulants
The hemostatic response enables 
mammals to control blood loss 
during vascular injury. Platelets 
adhere to macromolecules in exposed 
subendothelial tissue and aggregate 
to form a hemostatic plug, while local 
activation of plasma coagulation factors 
leads to generation of a ﬁbrin clot 
that reinforces the platelet aggregate. 
The coagulation cascade starts when 
exposed subendothelial tissue factor 
(TF) binds to activated factor VII 
(FVIIa). This complex activates factor 
X (forming FXa), which mediates 
the formation of minute amounts 
of thrombin that activate other 
coagulation proteases and additional 
platelets. Subsequently, by means of 
two ampliﬁcation loops (Figure 1), 
more thrombin is generated, which 
leads to ﬁbrinogen-to-ﬁbrin conversion 
and ﬁbrin deposition [8].
Tick feeding is hampered by the 
hemostatic response of the host. 
Therefore tick saliva contains an 
extensive selection of molecules 
that counteract coagulation, 
enhance ﬁbrinolysis, and inhibit 
platelet aggregation [7]. Traditional 
anticoagulant agents such as 
unfractionated heparin and vitamin 
K antagonists (e.g., warfarin) have a 
narrow therapeutic index, requiring 
frequent monitoring and dose 
adjustments [7]. Tick saliva presents 
a possible source of novel, and ideally 
more easily used, anticoagulant agents 
(Figure 1) [7].
Factor Xa inhibitors. Saliva from the 
soft tick Ornithodoros moubata contains a 
serine protease inhibitor of FXa—tick 
anticoagulant peptide (TAP). TAP is a 
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Five Key Papers in the Field
Hepburn et al., 2007 [40] After 
identiﬁcation of a speciﬁc activated 
C5 inhibitor, OMCI, the authors 
showed how this protein can be used 
in an experimental animal model for 
myasthenia gravis.
Paveglio et al., 2007 [50] Showed that 
a T cell inhibitor from tick saliva, Salp15, 
is able to prevent the development of 
pathological features in an animal model 
for atopic asthma.
Labuda et al., 2006 [55] Showed that 
an anti-tick vaccine, directed against 
the 64TRP cement protein in tick saliva, 
prevented lethal infection of mice 
with the tick-borne encephalitis virus, 
indicating that anti-tick vaccines could be 
used to combat tick-borne pathogens.
Ramamoorthi et al., 2005 [5] Showed
that B. burgdorferi, the causative agent 
of Lyme disease, uses a protein in tick 
saliva, Salp15, to establish an infection 
in the mammalian host, underscoring 
the complex tick–host–pathogen 
interactions that are involved in the 
development of Lyme disease.
 Waxman et al., 1990 [9] Identiﬁed 
the ﬁrst highly speciﬁc activated factor X 
inhibitor in tick saliva, TAP. This research 
has been the inspiration for numerous 
researchers working in the ﬁeld of 
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tight-binding speciﬁc FXa inhibitor that 
inhibits clotting of human plasma ex 
vivo [9]. The inhibitory characteristics 
and the high selectivity of recombinant 
forms of TAP (rTAP) for FXa are 
due to the interaction of rTAP with 
the active site as well as with regions 
remote from the active site pocket of 
FXa [10]. rTAP has been tested in 
a variety of animal models for both 
venous and arterial thrombosis [11–
13]. A recent study showed that rTAP, 
when fused to a single-chain antibody 
speciﬁcally targeting activated platelets 
(through binding to the platelet 
receptor GPIIb/IIIa), had highly 
effective antithrombotic properties 
in comparison to enoxaparin in a 
murine carotid artery thrombosis 
model. In addition, in contrast to 
conventional anticoagulants tested, the 
TAP–antibody fusion protein did not 
prolong bleeding time [14]. Future 
research should reveal whether this or 
similar approaches are equally effective 
and safe in humans. Other FXa 
inhibitors characterized in tick saliva 
are shown in Table 1 [15,16].
Tissue factor pathway inhibitors.
In view of the central role of TF in 
the initiation of coagulation in both 
physiological and pathological states, 
targeting TF may be an effective 
antithrombotic strategy. Tick saliva 
contains several TF pathway inhibitors 
(TFPIs) (Table 1) [7,17]. Recently, 
Ixolaris was identiﬁed in saliva from 
the deer tick Ixodes scapularis [17].
Ixolaris has two kunitz-like domains, 
a type of domain conserved in a wide 
family of serine protease inhibitors, 
and sequence homology to human 
TFPI [18]. In a rat model for 
venous thrombosis, administration 
of recombinant Ixolaris resulted 
in effective antithrombotic activity, 
without hemorrhage or bleeding [19]. 
Because of its fast and tight binding 
to FXa, giving rapid-acting, selective, 
and long-lasting effects, and the 
encouraging results in vivo, Ixolaris 
could serve as a template for potential 
new anticoagulant agents targeting the 
TF pathway. 
Direct thrombin inhibitors. In 
comparison with heparin (derivatives), 
which act via antithrombin, direct 
thrombin inhibitors more effectively 
inhibit clot-bound thrombin, which 
is likely to result in a stronger 
antithrombotic effect [20]. Several 
speciﬁc direct thrombin inhibitors 
have been characterized in tick saliva 
(Table 1) [7,21–24], but most have 
not yet been tested in vivo. Recently 
a new direct thrombin inhibitor, 
variegin [25], was characterized from 
the tropical bont tick, Amblyomma
variegatum, and shown to be structurally 
similar to, but much more potent than, 
hirulog, a 20-amino-acid synthetic 
thrombin inhibitor based on the 
natural leech peptide hirudin. Hirulog 
belongs to a class of drugs that have 
been approved for treatment of 
patients with acute coronary syndromes 
who are undergoing percutaneous 
coronary intervention [26].
Immunosuppressors
Cellular innate immune responses, 
depending on invariant receptors 
such as the Toll-like receptors, are 
one of the ﬁrst lines of defence 
against invading microbes. Another 
important innate defence system is 
the complement cascade. Activation 
of the complement system leads to 
opsonization of an invading pathogen 
as well as formation of the membrane 
attack complex that can lyse invading 
bacteria. The more speciﬁc adaptive 
immune response, which responds 
against pathogens that bypass the 
innate immune response, is triggered 
when activated antigen-presenting cells 
migrate to lymphoid tissue. In lymph 
nodes, antigen-presenting cells present 
processed antigen to T cells, which, 
upon activation, play a central role in 
cellular immune responses at the site of 
infection, or assist in the activation of B 
cells for the generation of an antigen-
speciﬁc humoral response.
Ticks acquire a blood meal over 
a period of days, allowing the host 
sufﬁcient time to generate anti-tick 
immune responses. The tick, in turn, 
has developed mechanisms to protect 
itself against host inﬂammation and 
immune responses [4]. In light of 
the central role of the complement 
cascade and T and B cells in many 
human diseases, we focus on speciﬁc 
tick salivary molecules that target these 
responses.
Complement inhibitors. The
complement system is involved 
in the pathogenesis of many 
autoimmune diseases, including 
rheumatoid arthritis, systemic lupus 
erythematosus, and multiple sclerosis, 
and also in ischemia-reperfusion 
injury as observed in acute myocardial 
infarction or ischemic stroke [27–
29]. Inhibitors of the complement 
cascade are therefore of potential 
clinical interest. Many agents inhibit 
complement factor 3 (C3) convertase 
early in the complement cascade, 
but this inhibition can result in 
immunosuppression, impairment of 
doi:10.1371/journal.pmed.0050043.g001
Figure 1. Schematic Overview of the Coagulation Cascade
The two major ampliﬁcation loops in the coagulation cascade are depicted. The ﬁrst ampliﬁcation 
loop consists of TF-FVIIa-mediated factor IX (FIX) activation, which leads to the generation of more 
FXa. A second ampliﬁcation loop is formed by the activation of factor XI (FXIa) by thrombin, which 
results in more activated FIX (FIXa), and, subsequently, additional FXa generation. The right panel 
indicates how selected tick proteins exert their anticoagulant effect.
FIIa, activated factor II; FVa, activated factor V; FVIIIa, activated factor VIII.PLoS Medicine  |  www.plosmedicine.org 0204 February 2008  |  Volume 5  |  Issue 2  |  e43
Table 1. Anticoagulants and Immunosuppressors in Tick Saliva
Molecule Accession
number(s)
Tick Species Target(s) Additional Information Type of 
Experiments
Animal
Disease
Model(s)
Reference(s)
Anticoagulants
Faxtor Xa inhibitors
TAP GI1421459 O. moubata FXa Slow tight-binding 60-amino-
acid serine protease
Human in vitro and 
animal in vivo studies
Arterial
and venous 
thrombosis
[9,11]
Salp14 AAK97824 I. scapularis FXa RNAi of Salp14 in I. scapularis
resulted in 60%-80% reduction 
of anti-FXa activity of I. 
scapularissaliva
Human in vitro 
studies
[16]
FXa inhibitor (FXaI) AAN76827 O. savignyi FXa Recombinant FXaI consists of 
60 amino acids and inhibits 
FXa by 91%. FXaI shares 78% 
homology to TAP.
Human in vitro 
studies
[15]
Tissue factor pathway inhibitors
Ixolaris AAK83022 I. scapularis Inhibits TF/
FVIIa-induced
activation
of FX
Sequence homology to human 
TFPI, 2 kunitz-like domains
Human in vitro 
studies and animal in 
vivo studies
Venous
thrombosis
[18,19]
Penthalaris AAM93638 I. scapularis Inhibits TF/
FVIIa-induced
activation
of FX
Sequence homology to human 
TFPI, 5 tandem kunitz domains
Human in vitro 
studies
[17]
Direct thrombin inhibitors
Microphilin Not done Boophilus
microplus
Thrombin
exosite 1
Small thrombin inhibitor (1,8 
kDa)
Animal in vitro 
studies
[21]
Savignin AAL37210 O. savignyi Thrombin
active site and 
exosite 1
2 kunitz-like domains Human in vitro 
studies
[23]
Ornithodorin P56409 O. moubata Thrombin
active site and 
exosite 1
2 kunitz-like domains 
resembling the basic pancreatic 
trypsin inhibitor 
In silico studies [24]
Madanin 1 and 2 AAP04349, AAP04350 Haemaphysalis
longicornis
Thrombin
exosite 1
No homology to other direct 
thrombin inhibitors, estimated 
KD of 25 and 34.5 nM, 
respectively
Human in vitro 
studies
[22]
Variegin Described in [25], not 
yet submitted
A. variegatum Thrombin
active site and 
exosite 1
A polypeptide of 32 amino 
acids that is a potent inhibitor 
of thrombin and is structurally 
and functionally similar to 
hirulog
Human in vitro 
studies
[25]
Immunosuppressors
Complement inhibitors
OMCI AAT65682 O. moubata C5 A 16 kDa protein with a 
lipocalin fold that interferes 
with C5 activation through 
prevention of interaction of C5 
with C5 convertase
Human in vitro 
studies and animal in 
vivo studies
Myasthenia
gravis
[34,39,40]
Isac AAF81253 I. scapularis C3 convertase A 18.5 kDa protein that acts 
as a regulator of complement 
activation, similar to human 
factor H, by interacting with C3 
convertase
Human in vitro 
studies
[37]
IRAC 1 and 2 AAX63389, AAX63390 I. ricinus Alternative
complement
pathway
Isac paralogues, also inhibiting 
the alternative complement 
pathway
Human in vitro 
studies
[35]
Salp20 AAK97820 I. scapularis C3 convertase Like Isac, and IRAC 1 and 2, 
Salp20 and its homologues 
are part of a larger Isac protein 
family
Human in vitro 
studies
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opsonization, or immune complex 
deposition. Novel complement 
inhibitors should therefore preferably 
inhibit the complement cascade 
downstream of complement factor 5 
(C5), allowing the upstream cascade 
to proceed physiologically. Early 
randomized controlled clinical trials 
studying the effect of an antibody 
targeting C5 in acute myocardial 
infarction showed promising results 
[30,31], although a more recent 
randomized controlled trial showed no 
beneﬁcial effect on all-cause mortality 
of a C5-antibody compared to placebo 
[32]. A similar antibody was shown 
to be effective in the treatment of 
autoimmune diseases [33]. 
Tick saliva contains many molecules 
that speciﬁcally inhibit complement 
activation (Table 1) [34–38]. A 
promising tick complement inhibitor 
is the C5 activation inhibitor from the 
soft tick O. moubata, OMCI [34,39]. 
OMCI inhibits C5 activation by 
interfering with C5 convertase [39], 
and has been shown to inhibit human 
complement hemolytic activity and the 
development of pathological features 
in a rodent model for autoimmune 
myasthenia gravis [40]. 
B cell inhibitors. The I. ricinus B 
cell inhibitory protein (BIP) is one of 
the tick salivary proteins that suppress 
proliferation of murine B cells (Table 
1) [41,42]. Suppression of B cell 
responses beneﬁts the tick by inhibiting 
speciﬁc anti-tick antibody responses 
that could lead to rejection by the 
host. In addition, B cells are unable 
to respond adequately to Borrelia
burgdorferi antigens in the presence of 
BIP, suggesting that B. burgdorferi might 
also beneﬁt from BIP-mediated B cell 
suppression. Speciﬁc inhibition of B 
cells has been shown to be effective in 
clinical studies of lymphoproliferative 
disorders and autoimmune diseases, 
such as rheumatoid arthritis and 
multiple sclerosis [43,44]. In order 
to serve as a template for novel 
drugs speciﬁcally targeting B cells, 
tick B cell inhibitors need further 
characterization.
T cell inhibitors. The I. scapularis 
15 kDa salivary protein, Salp15, is an 
example of a feeding-induced protein 
that inhibits the activation of T cells 
(Table 1) [45–49]. Salp15 speciﬁcally 
binds to the CD4 molecule on CD4+
T (helper) cells, which results in 
inhibition of T cell receptor–mediated 
signaling, leading to reduced 
interleukin-2 production and impaired 
T cell proliferation [46]. In an 
experimental mouse model of allergic 
airway disease, Salp15 prevented the 
development of atopic asthma [50], 
suggesting that Salp15 might be used 
to modulate atopic disease as well as T 
cell–driven autoimmune diseases. We 
have shown that Salp15 also inhibits 
Table 1. continued
Molecule Accession
number(s)
Tick Species Target(s) Additional Information Type of 
Experiments
Animal
Disease
Model(s)
Reference(s)
Immunosuppressors continued
T cell inhibitors
Salp15 AAK97817(I.
scapularis),
ABU93613 (I. ricinus)
I. scapularis, 
I. ricinus
CD4+T cells Binds to CD4, impairing TCR-
induced signaling and resulting 
in impaired IL-2 production and 
T cell proliferation
Animal in vitro and in 
vivo studies
Atopic asthma [45,46]
Dendritic cells Binds to DC-SIGN on dendritic 
cells
Human in vitro 
studies
[51]
B. burgdorferi 
OspC
Also binds B. burgdorferi OspC,
protecting the spirochete from 
antibody-mediated killing
Animal in vitro and in 
vivo studies
[5]
IL-2 binding protein Unknown I. scapularis IL-2 A protein in tick saliva that 
inhibits proliferation of human 
T cells and CTLL-2 cells
Animal and human in 
vitro studies
[47]
Iris CAB55818 I. ricinus T lymphocytes 
and
macrophages
Modulates T lymphocyte and 
macrophage responsiveness 
by inducing Th2-type 
responses and by inhibiting 
the production of pro-
inﬂammatory cytokines
Animal and human in 
vitro studies
[49]
Several serine 
proteases
Has also been shown to have 
anti-hemostatic responses and 
has been tested as an anti-tick 
vaccine candidate
Animal and human 
in vitro studies and 
in vivo animal studies
[52,58]
Sialostatin L GI22164282 I. scapularis Cytotoxic T 
lymphocytes
Speciﬁcally inhibits cathepsin 
L activity
Animal in vitro 
studies
[48]
B cell inhibitors
B cell inhibitory protein  Unknown I. ricinus B cells Inhibits B. burgdorferi antigen-
induced proliferation of B cells
Animal in vitro 
studies
[42]
B cell inhibitory factor  Described in [41], not 
yet submitted
Hyalomma
asiaticum
asiaticum
B cells Inhibits LPS-induced 
proliferation of B cells
Animal in vitro 
studies
[41]
CTLL-2, cytotoxic T lymphocyte cell line 2; IL-2, interleukin 2; KD, binding constant; kDa, kilo Dalton; RNAi, RNA interference; TCR, T cell receptor.
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inﬂammatory cytokine production by 
human monocyte-derived dendritic 
cells by interacting with the C-type 
lectin receptor DC-SIGN [51], 
indicating that Salp15 has the potential 
to modulate human adaptive immune 
responses. Iris, an immunosuppressive 
protein from I. ricinus, has been 
shown to modulate T cell responses 
through inhibition of interferon-γ and 
to inhibit interleukin-6 and tumor 
necrosis factor-α production by human 
macrophages [49]. In addition, Iris 
also has been shown to have anti-
hemostatic effects by inhibiting several 
serine proteases involved in the 
coagulation cascade and ﬁbrinolysis 
[52].
New Strategies to Prevent Tick-
Borne Diseases
Understanding the importance of 
speciﬁc tick salivary proteins for 
attachment to the host and for 
transmission of pathogens may permit 
us to develop new strategies (e.g., anti-
tick vaccines) for preventing tick-borne 
diseases. The idea of a tick-antigen-
based vaccine is supported by the 
observation that repeated exposure 
of certain animals to tick bites results 
in an inability of ticks to successfully 
take a blood meal [45]. These animals, 
as well as humans who develop 
hypersensitivity after repeated tick 
bites [49], are less likely to be infected 
by tick-borne pathogens [53]. Ideally, 
an anti-tick vaccine would protect 
against infestation by a wide range of 
doi:10.1371/journal.pmed.0050043.g002
Figure 2. Diagram Showing How an Anti-Salp15 Vaccine Could Prevent Transmission of B. burgdorferi
During tick feeding and early mammalian infection, B. burgdorferi expresses OspC, which binds to Salp15 in tick saliva. This binding acts as a shield and 
protects the spirochete from killing by the host. In addition, Salp15 has been shown to directly inhibit dendritic cell and T cell activation, which could 
facilitate tick feeding. Salp15 antibodies are likely to bind to Salp15 that has previously bound to OspC on the surface of B. burgdorferi in the tick salivary 
gland and could thereby enhance clearance by host phagocytic immune cells. Obviously, the Salp15 antibodies would need to recognize a Salp15 
epitope other than the epitope that is required for binding of Salp15 to OspC. Similarly, if anti-Salp15 antibodies were to bind to free Salp15, they could 
neutralize the immunosuppressive effects of Salp15, which could hamper tick feeding and thereby transmission of B. burgdorferi from the tick to the 
host. Lastly, if anti-Salp15 antibodies were to inhibit binding of Salp15 to Borrelia OspC, this would render the spirochete susceptible to pre-existing or 
newly generated immunoglobulins. Importantly, Salp15 was originally identiﬁed by screening of a tick salivary gland cDNA expression library with tick 
immune rabbit sera, suggesting that antibodies against Salp15 may participate in tick rejection. 
DC, dendritic cell; MHC, major histocompatibility complex; MΦ, macrophage; TCR, T cell receptor.PLoS Medicine  |  www.plosmedicine.org 0207 February 2008  |  Volume 5  |  Issue 2  |  e43
tick species and prevent transmission 
of multiple tick-borne pathogens. 
Discussing all tick antigens that have 
been assessed in vaccination trials is 
beyond the scope of this article. For 
an overview of the current stage of 
development of anti-tick vaccines, there 
is an excellent review available [54]. 
An interesting example of an anti-tick 
vaccine that also protects against the 
transmission of a tick-borne pathogen 
is a vaccine targeting the salivary 
cement protein, 64P, from the tick 
Rhipicephalus appendiculatus [55,56].
Tick feeding on animals immunized 
with truncated recombinant forms 
of 64P (64TRP) resulted in local 
inﬂammatory responses and protection 
against infestation by a wide range of 
tick species [56]. Importantly, 64TRP-
vaccinated mice challenged with tick-
borne encephalitis virus (the most 
important human vector-borne viral 
infection in Europe [57]) through 
tick bite were protected from lethal 
encephalitis [55].
Proteins that enhance tick feeding 
may also modulate host immune 
responses to pathogens, thus playing 
a double role in transmission. For 
example, an I. scapularis tick can 
introduce both Salp15 and B. burgdorferi
into the host skin. As described earlier, 
Salp15 may enhance tick feeding by 
inhibiting host immune responses 
to tick antigens. In addition, the B.
burgdorferi outer surface protein C 
(OspC) has been shown to bind to 
Salp15 in tick saliva [5]. This binding 
acts as a shield that protects the 
spirochete against the host immune 
response (Figure 2). Salp15 would 
therefore be a candidate to consider 
for immunization studies. Also, the 
pleiotropic protein Iris, that not only 
modulates T cell responses, but also 
speciﬁcally disrupts coagulation [52], 
could be an interesting candidate. 
Recently, it was shown that vaccinating 
rabbits with Iris partially protected 
these rabbits from tick infestations 
[58].
Conclusion
Tick saliva is a potential source for 
novel pharmacological agents that 
could be useful for clinical practice. 
Future research must conﬁrm 
whether these speciﬁc and potent 
molecules, with promising results in 
animal models and in human ex vivo 
experiments, are effective in humans 
in vivo. The molecules discussed 
are only a selection of the many 
physiologically active molecules that 
have been identiﬁed and characterized. 
However, this selection illustrates the 
impressive resourcefulness that ticks 
display to modulate host processes, and 
demonstrates how we could use these 
molecules to our beneﬁt. Undoubtedly, 
future research on tick–host and tick–
host–pathogen interactions will reveal 
even more potential molecules that 
could be used in clinical practice.  
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